This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ASNS / Asparagine synthetase [glutamine-hydrolyzing] · IHC design guide
Design Immunohistochemistry for ASNS
Plan ASNS chromogenic IHC around cytoplasmic staining in several tissue types (HPA tissue IHC). Use cell-specific controls and check antibody epitope coverage across the 3 annotated isoforms (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ASNS Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining in pancreatic exocrine and gastric glandular cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A03302-2) | |
| Positive control | Cerebellum+4 more · see all | |
| Negative control | Adrenal gland+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining and RNA show medium consistency; verify with controls (HPA tissue IHC) | |
| Regulation | Pancreas-enhanced RNA expression (HPA RNA) | |
| Isoform / epitope | 3 isoforms; antibody epitope coverage is unspecified (UniProt) |
Section 1
Recommended ASNS IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet A03302-2) with three published ASNS IHC protocols (PMC9424662; PMC10393983; PMC8440958).
| Sample | Paraffin-embedded human gastric carcinoma tissue; fixative not specified (datasheet A03302-2) |
| Fixation | Image fixative and duration unreported (datasheet A03302-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A03302-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A03302-2) |
| Primary antibody | Rabbit anti-ASNS, 2-5 μg/ml (datasheet A03302-2) |
| Primary incubation | Overnight at 4 °C (datasheet A03302-2) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A03302-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ASNS-positive staining in purkinje cells of cerebellum (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in several different tissue types, including pancreas, brain and stomach. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval (datasheet A03302-2); the published protocols specify antigen repair, heat-induced retrieval, or 20 min HIER (PMC9424662; PMC10393983; PMC8440958).
Section 2
What Is the Expected ASNS Staining Pattern?
ASNS should show predominantly cytoplasmic staining in several tissue types, including pancreatic exocrine glandular cells, cerebellar Purkinje cells, gastric glandular cells and placental trophoblastic cells (HPA: tissue IHC). Cytosolic localization is supported by ICC-IF, while UniProt does not annotate a subcellular location or a transmembrane segment (HPA: subcellular; UniProt P08243 topology). Treat this as a reference pattern: HPA rates tissue staining Approved, with medium RNA concordance and external verification pending (HPA: tissue IHC reliability).
| Clear cytoplasmic signal in pancreatic exocrine glandular cells, with the expected tissue architecture preserved. | This matches a cell type scored High by tissue IHC and the supported cytosolic location in ICC-IF (HPA: pancreas tissue IHC; HPA: subcellular). Compare staining with a control section processed in the same run (general IHC practice). |
| Predominantly nuclear or sharply membranous staining in otherwise well-preserved cells. | This departs from HPA’s cytoplasmic tissue profile and supported cytosolic ICC-IF location (HPA: tissue IHC; HPA: subcellular). Check counterstain, detection background and antibody specificity before interpreting it as ASNS; UniProt reports no transmembrane segment (UniProt P08243 topology; general IHC practice). |
| Strong signal in cells listed as undetected, such as adrenal glandular cells or lung alveolar cells. | HPA scores these specific cell types Not detected; that designation does not apply to every cell in either tissue (HPA: adrenal gland and lung tissue IHC). Review cell identification and controls for cross-reactivity or endogenous chromogenic activity (general IHC practice). |
| Color spreads across tissue and extracellular spaces without defined cytoplasmic cell boundaries. | That distribution is less consistent with the reported cytoplasmic profile (HPA: tissue IHC). Consider nonspecific background or detection chemistry; inspect a section lacking primary antibody and review blocking, washing and chromogen development (general IHC practice). |
| No detectable signal in pancreatic exocrine glandular cells on a technically intact section. | This conflicts with their High HPA score, but one negative run does not establish absent ASNS (HPA: pancreas tissue IHC). Confirm that a known-positive control stains, then review antibody dilution, retrieval and detection using the antibody’s IHC-P instructions (general IHC practice). |
💡Expected ASNS appearanceCall a result consistent with ASNS when distinct cytoplasmic staining appears in HPA High cells such as pancreatic exocrine glandular cells; isolated nuclear or membranous color, or strong color in an HPA-undetected cell type, warrants control review (HPA: tissue IHC; HPA: subcellular; UniProt P08243 topology).
| Tissue and cell selection | HPA scores Purkinje cells, pancreatic exocrine glandular cells, trophoblastic cells, gastric glandular cells and tonsillar germinal center cells High (HPA: tissue IHC). Its undetected calls are cell-specific: kidney glomerular cells and liver cholangiocytes, for example, are not whole-organ negative controls (HPA: tissue IHC). |
| Location evidence and assay boundary | Tissue IHC describes cytoplasmic staining; ICC-IF supports a cytosolic location (HPA: tissue IHC; HPA: subcellular). UniProt supplies no subcellular annotation and reports no transmembrane segment (UniProt P08243 topology). Use these observations to assess compartment, without assuming identical staining quality across assays (general IHC practice). |
| Antibody evidence | HPA lists two antibodies with Approved IHC status, HPA029318 and HPA064737; the overall tissue profile has medium agreement with RNA and awaits external verification (HPA: antibodies; HPA: tissue IHC reliability). An Approved designation supports comparison with the reported pattern but does not prove every stained cell is specific (general IHC practice). |
| Molecular features | UniProt lists three isoforms, a chain spanning residues 2–561 and modified residues including positions 385, 545 and 557 (UniProt P08243 isoforms, processing and modified residues). The payload gives no antibody epitope, so these features cannot predict isoform coverage, retrieval response or staining intensity for a particular antibody. |
| IF/ICC Q&A: what should be visible? | Expect cytosolic fluorescence when the ICC-IF assay detects ASNS: HPA calls the cytosol its supported main location and lists images from A-431, U-251MG, U2OS, MCF-7 and SK-MEL-30 (HPA: subcellular). This localization answers the IF/ICC pattern question; the present tissue interpretation remains based on IHC (HPA: tissue IHC). |
| Situation | Likely cause | Next action |
|---|---|---|
| Known-positive pancreatic exocrine cells are blank. | The run may have insufficient detectable signal; HPA scores these cells High (HPA: pancreas tissue IHC). | Check a same-run positive control and the antibody’s stated IHC-P dilution and retrieval settings; confirm detection reagents and timing (general IHC practice). |
| Both expected positive cells and the no-primary control show widespread color. | Shared color suggests background from the detection system or tissue endogenous activity, rather than a cell-specific ASNS pattern (general IHC practice; HPA: tissue IHC pattern). | Review endogenous-activity blocking appropriate to the chromogen, wash steps and chromogen development; repeat controls alongside tissue (general IHC practice). |
| Undetected reference cells stain strongly. | An HPA-undetected call applies to the listed cell type; apparent disagreement may reflect cell misidentification or nonspecific signal (HPA: tissue IHC; general IHC practice). | Recheck morphology and the precise HPA cell label, then compare no-primary and positive controls before assigning ASNS positivity (general IHC practice). |
| Signal appears mainly nuclear or outlines cell membranes. | The compartment conflicts with the cytoplasmic tissue pattern and supported cytosolic ICC-IF location (HPA: tissue IHC; HPA: subcellular). | Verify focus and counterstain, compare the no-primary control, and reassess specificity with the IHC-validated antibody (general IHC practice). |
| Tissue sections stain unevenly within a run. | Variable section handling or reagent coverage can produce uneven chromogenic staining (general IHC practice); HPA provides no target-specific fixation-sensitivity finding (HPA: tissue IHC scope). | Inspect section integrity and reagent coverage, then compare only areas processed under matching conditions (general IHC practice). |
| A dim cell population is scored simply positive or negative. | HPA reports Low staining in some cells, including hippocampal neurons and cardiomyocytes, and Medium staining in caudate neurons (HPA: tissue IHC). | Record cell type and intensity separately, compare with same-run controls, and avoid treating weak color alone as a specificity test (general IHC practice). |
Experiment evidence
IHC & IF images showing ASNS staining
A03302-2 · IHCIHC analysis of Asparagine synthetase/ASNS using anti-Asparagine synthetase/ASNS antibody (A03302-2). Asparagine synthetase/ASNS was detecte
A03302-2 · IHCIHC analysis of Asparagine synthetase/ASNS using anti-Asparagine synthetase/ASNS antibody (A03302-2). Asparagine synthetase/ASNS was detecte
A03302-2 · IFIF analysis of Asparagine synthetase/ASNS using anti-Asparagine synthetase/ASNS antibody (A03302-2). Asparagine synthetase/ASNS was detected
M03302 · IHCImmunohistochemical analysis of paraffin-embedded human bladder, using ASNS Antibody.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000070669-ASNS/tissue/cerebral+cortex#imid_8026223
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000070669-ASNS/tissue/colon#imid_8026157
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000070669-ASNS/tissue/liver#imid_8026166
HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000070669-ASNS/tissue/pancreas#imid_8026109
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA004924; green = ASNS, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA004924; green = ASNS, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ASNS IHC & IF
🧪Run stomach first: glandular cells should stain (HPA: High in stomach glandular cells). Use bronchus respiratory epithelial cells as the negative tissue (HPA: Not detected); on the stomach slide, compare glandular staining with non-glandular cells as an internal background check, without assuming those cells are ASNS-negative.
Positive control tissue: Cerebellum (Purkinje cells, HPA High)
Negative control tissue: Adrenal gland (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ASNS in A-431, U-251MG, U2OS, MCF-7, SK-MEL-30, with annotated localisation: Cytosol (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and a concentration-matched rabbit IgG control appropriate to the primary antibody (selected-SKU caption: rabbit primary antibody). Use an ASNS-knockout specimen as a biological negative; for HRP/DAB detection, quench endogenous peroxidase and inspect the no-primary slide for residual staining (selected-SKU caption: HRP/DAB detection).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected-SKU paraffin-section caption does not report a fixative (selected-SKU caption: fixative not stated). The gastric carcinoma IHC example used heat retrieval in EDTA at pH 8.0, but it does not establish whether ASNS staining depends on retrieval (selected-SKU caption: EDTA heat retrieval). HPA reports cytosolic ICC-IF staining, but the supplied evidence does not establish that frozen-section IHC or IF is easier; in gastric tissue, check glandular staining against luminal material and any residual HRP/DAB background (HPA: Cytosol supported; selected-SKU caption: HRP/DAB detection).
HPA tissue IHC evidence for ASNS
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Purkinje cells | High | Protein (IHC) | HPA → |
| Pancreas | Exocrine glandular cells | High | Protein (IHC) | HPA → |
| Placenta | Trophoblastic cells | High | Protein (IHC) | HPA → |
| Stomach | Glandular cells | High | Protein (IHC) | HPA → |
| Tonsil | Germinal center cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Endometrium | Cells in endometrial stroma | Not detected | Protein (IHC) | HPA → |
| Fallopian tube | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ASNS IHC Tips
Troubleshoot ASNS staining in paraffin sections by checking retrieval, cellular distribution, controls, and scoring before interpreting differences between specimens.
Which retrieval conditions should I try first for weak ASNS staining in paraffin sections?
Start with heat mediated retrieval in EDTA at pH 8.0 (datasheet A03302-2). The selected paraffin section image used that retrieval before overnight incubation at 4°C with 2 μg/ml primary antibody (caption A03302-2). Keep section thickness, heating, cooling, and detection conditions consistent while comparing a weak specimen with a positive control, such as stomach glandular cells (HPA: High in stomach glandular cells). If staining remains weak, compare a second retrieval condition on adjacent sections as a controlled fallback, recording both signal and tissue damage (standard IHC practice). Evaluate cytoplasmic staining within intact cells rather than judging retrieval by total DAB intensity (HPA tissue IHC: cytoplasmic expression).
Could fixation explain uneven ASNS staining across my paraffin sections?
ASNS specific sensitivity to fixation is unknown from the supplied evidence; the selected image describes a paraffin section but does not state its fixative (caption A03302-2). Record fixative, time in fixative, processing schedule, section age, and retrieval conditions for each case before attributing uneven staining to biology (standard IHC practice). Compare serial sections processed together, using EDTA at pH 8.0 and the same detection conditions (datasheet A03302-2). If staining varies with processing history, repeat staining on matched material and assess tissue morphology alongside signal (standard IHC practice). Neither the reported cytoplasmic pattern nor the protein’s modifications establishes a fixation effect (HPA tissue IHC; UniProt P08243).
How should I assess nuclear or membranous ASNS staining in tissue?
Expect predominantly cytoplasmic staining in paraffin sections (HPA tissue IHC: cytoplasmic expression); independent cell imaging supports a cytosolic location (HPA subcellular: Cytosol, supported). ASNS has no annotated transmembrane segment, so a sharp membrane outline needs scrutiny before being called target signal (UniProt P08243 topology). Check whether the apparent nuclear or membrane pattern persists in intact cells away from section folds and edges, then compare it with a no primary control (standard IHC practice). Score the cytoplasmic compartment separately from unexpected patterns, and document the affected cell type and distribution (standard IHC practice). If the atypical pattern persists, confirm its specificity with an independent antibody or orthogonal evidence (standard IHC practice).
Can this stain distinguish ASNS isoforms or modifications?
Do not assign a paraffin section stain to one ASNS isoform without an epitope map and isoform specific validation; the record lists 3 isoforms (UniProt P08243). The protein contains a glutamine amidotransferase type 2 region at residues 2–191 and an asparagine synthetase region at 213–536 (UniProt P08243 domains). Reported modifications include acetylation at residue 385 and phosphorylation at 545 and 557, but their effects on this antibody’s staining are unestablished (UniProt P08243 modified residues). If an unusual pattern motivates an isoform claim, obtain the antibody’s mapped epitope and compare isoform sequence coverage before testing that claim with isoform specific material (standard IHC practice).
How can I follow up an ASNS IHC pattern with multiplex IF?
Treat IF as a separate assay and pair ASNS with a marker that identifies the cell population under study, such as a glandular cell marker when examining stomach glands (HPA: High in stomach glandular cells). Choose spectrally separated fluorophores after checking unstained tissue for autofluorescence, then use single stain controls to assess bleed through (standard IF practice). ASNS is supported as cytosolic and has no annotated transmembrane segment, so allow antibody access to the intracellular compartment through an appropriately validated permeabilisation step (HPA subcellular: Cytosol, supported; UniProt P08243 topology). Record fixation and permeabilisation for the IF assay separately; the selected paraffin IHC caption does not establish IF conditions (caption A03302-2).
What should I check when DAB appears throughout the section?
Compare the stained section with a no primary control and inspect whether DAB is diffuse, concentrated at section edges, or confined to damaged areas (standard IHC practice). Check blocking and washing first: the selected paraffin section workflow used 10% goat serum before primary antibody and a peroxidase linked detection system with DAB (caption A03302-2). Include a peroxidase blocking step and assess endogenous enzyme signal in the no primary control; these are general chromogenic IHC checks, not evidence of an ASNS specific effect (standard IHC practice). Titrate primary antibody around the demonstrated 2 μg/ml condition while holding retrieval and development constant (caption A03302-2; standard IHC practice). Retain only cell associated cytoplasmic signal for interpretation (HPA tissue IHC: cytoplasmic expression).
How should I score heterogeneous ASNS staining across specimens? ⚠ ANSWER MARKED FOR VERIFICATION
Define the scored cell population and compartment before reviewing outcomes; the reported tissue pattern is cytoplasmic, with high staining in stomach glandular cells and pancreatic exocrine glandular cells (HPA tissue IHC). For chromogenic sections, report the percentage of positive target cells and an H-score based on staining intensity, with the scoring thresholds stated explicitly (standard IHC practice). If counting positive cells per mm², normalize to the area of viable tissue or the defined cell compartment, and report that denominator (standard IHC practice). Apply the same imaging and DAB development settings across batches, exclude folds and necrotic regions, and retain negative controls for threshold setting (standard IHC practice).
How do I separate genuine ASNS positivity from staining artefacts?
Look for cell associated cytoplasmic signal in intact tissue, consistent with the reported tissue pattern and supported cytosolic location (HPA tissue IHC; HPA subcellular: Cytosol, supported). Stomach glandular cells provide a reported high staining comparator, whereas adrenal gland glandular cells are listed as not detected; neither result guarantees the outcome for every specimen or antibody (HPA tissue IHC). Suspect artefact when signal tracks cut edges, folds, necrosis, or a no primary control, and investigate endogenous peroxidase when DAB appears without primary antibody (standard IHC practice). Interpret unexpected nuclear or membrane dominant staining cautiously because ASNS has no annotated transmembrane segment (UniProt P08243 topology). Confirm consequential findings with an independent assay (standard IHC practice).
Boster reagents
Best ASNS / Asparagine synthetase [glutamine-hydrolyzing] IHC Antibodies
Two anti-ASNS antibodies have human paraffin-section IHC images (catalog IHC captions); one also has a human intestinal cancer IF image (A03302-2 IF caption). Both list Human, Mouse and Rat reactivity (catalog applications/reactivity).
Real IHC data
Anti-Asparagine synthetase/ASNS Antibody ®
Cat # A03302-2
Real IHC data
Anti-ASNS/Asparagine Synthetase Rabbit Monoclonal Antibody
Cat # M03302
A03302-2 has IHC images from paraffin sections of human gastric carcinoma, lung cancer and testicular germ cell tumors, plus an IF image from a paraffin section of human intestinal cancer (A03302-2 image captions). M03302 has an IHC image from paraffin-embedded human bladder and lists ICC/IF among its applications, but has no IF image in the payload (M03302 image captions and applications).
Which to pick: For tissue IHC, choose A03302-2 when its documented retrieval and detection conditions are useful: EDTA pH 8.0 heat retrieval, 2 μg/ml primary antibody and DAB detection; M03302 also has a human paraffin-section IHC image, but its caption gives no processing conditions (A03302-2 and M03302 IHC captions). For IF, A03302-2 has an image; for ICC, M03302 lists that application, without an ICC image in the payload (A03302-2 IF caption; M03302 applications and image captions). Both list Human, Mouse and Rat reactivity, while their supplied images show human samples only; the fixative is unreported in both IHC captions (catalog reactivity; IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P08243 (ASNS_HUMAN, Asparagine synthetase [glutamine-hydrolyzing]).
- Human Protein Atlas. ASNS tissue IHC expression (reliability: Approved).
- Human Protein Atlas. ASNS subcellular location (ICC-IF): Localized to the cytosol..
- Human Protein Atlas. ASNS antibody validation summary (3 antibodies).
- ASNS can predict the poor prognosis of clear cell renal cell carcinoma. Frontiers in oncology 2022 — PMC9424662.
- From ALL to Myeloid and NK Malignancies: Operationalizing "ASNS-Low" for L-Asparaginase Repurposing and Combination Therapy. Biomolecules 2026 — PMC13296854.
- NUCKS1, a LINC00629-upregulated gene, facilitated osteosarcoma progression and metastasis by elevating asparagine synthesis. Cell death & disease 2023 — PMC10393983.
- Proteomics Analysis Identified ASNS as a Novel Biomarker for Predicting Recurrence of Skull Base Chordoma. Frontiers in oncology 2021 — PMC8440958.
- PubMed PMID:2886907 — UniProt-cited evidence.
- PubMed PMID:2565875 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ASNS (Asparagine synthetase [glutamine-hydrolyzing]). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A03302-2). Validated IHC antibody: A03302-2 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Purkinje cells); negative Adrenal gland. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human gastric carcinoma tissue; fixative not specified (datasheet A03302-2); 2. Fixation: Image fixative and duration unreported (datasheet A03302-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A03302-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A03302-2); 8. Primary antibody: Rabbit anti-ASNS, 2-5 μg/ml (datasheet A03302-2); 9. Primary incubation: Overnight at 4 °C (datasheet A03302-2). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Staining and RNA show medium consistency; verify with controls (HPA tissue IHC); Isoform / epitope: 3 isoforms; antibody epitope coverage is unspecified (UniProt); Regulation: Pancreas-enhanced RNA expression (HPA RNA). Evidence: UniProt P08243, HPA tissue IHC · Approved, HPA ICC-IF · cytosol., Datasheet A03302-2, PMC9424662, PMC10393983. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ASNS/immunohistochemistry-ihc-guide.